, Applicability of the World Health Organization recommended new shorter 93 regimen in a multidrug-resistant tuberculosis high burden country, Eur. Respir. J, vol.49, p.94, 2017.
, Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations, American Journal of Respiratory and Critical Care Medicine, vol.194, issue.8
DOI : 10.1164/rccm.201605-1080LE
, Successful ???9-month Bangladesh regimen??? for multidrug-resistant tuberculosis among over 500 consecutive patients, The International Journal of Tuberculosis and Lung Disease, vol.18, issue.10, pp.1180-1187
DOI : 10.5588/ijtld.14.0100
, High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses, The International Journal of Tuberculosis and Lung Disease, vol.18, issue.10, pp.1188-1194, 2014.
DOI : 10.5588/ijtld.13.0075
, High effectiveness of a 12-month regimen for MDR-TB patients in 105
, World Health Organization treatment 108 guidelines for drug-resistant tuberculosis, 2016 update, European Respiratory Journal, vol.49, issue.3, pp.10-1183, 2017.
, Population-based resistance of Mycobacterium tuberculosis isolates to 111 pyrazinamide and fluoroquinolones: results from a multicountry surveillance project, p.112
, Concordance of <I>Mycobacterium tuberculosis</I> fluoroquinolone resistance testing: implications for treatment, The International Journal of Tuberculosis and Lung Disease, vol.19, issue.3, pp.339-341, 2015.
DOI : 10.5588/ijtld.14.0814
, Specific gyrA gene mutations predict poor treatment outcome in MDR-TB, J, p.116
DOI : 10.1093/jac/dkv360
URL : https://academic.oup.com/jac/article-pdf/71/2/314/6993252/dkv360.pdf
, Effectiveness and safety of bedaquiline-containing regimens in 126 the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study, Eur, vol.127